EGFR and non-small cell lung carcinoma: Remarkably, the encouraging results of the Chrysalis trial led to the ongoing PAPILLON trial which compares the efficacy and safety of amivantamab in combination with chemotherapy in the first-line setting of NSCLC with EGFR exon 20 insertions [62,63].